Treatment of midgestational placental haemorrhage with recombinant factor VIIa

Treatment of midgestational placental haemorrhage with recombinant factor VIIa.

Recombinant factor VIIa in massive obstetric haemorrhage.

the severity of hypertensive attacks. The other recommended agent phentolamine, a short-acting alpha blocker, could not be used due to unavailability in our institution during this case. Magnesium sulphate is routinely used to control arrhythmias and hypertension in patients undergoing cardiovascular surgery and in the Caesarean section of preeclamptic patients or ICU patients. However, magnesi...

Use of recombinant factor VIIa for major haemorrhage.

EDITOR: Haemorrhage associated with trauma and surgery remains a significant cause of death. The development of coagulopathic bleeding is often difficult to manage. Recombinant-activated factor VII (rFVIIa, NovoSeven®; Novo Nordisk, Bagsvaerd, Denmark), which is structurally similar to the naturally occurring activated coagulation factor VII, is licensed for use in patients with haemophilia A o...

Intracerebral haemorrhage and recombinant factor VIIa: not so good news!

Recombinant factor VIIa for life-threatening post-partum haemorrhage.

The treatment of life-threatening post-partum haemorrhage (PPH) still remains challenging, and hysterectomy may be required to control the bleeding. We present 12 cases of severe PPH treated with recombinant factor VIIa (rFVIIa). We briefly describe the causes of the haemorrhage and the medical and surgical interventions before rVIIa administration. In 11 women there was a partial or good respo...